Fast Track Initiative

RegCell is a biotechnology company focused on developing innovative therapeutic technologies to address autoimmune diseases and cancer. The company specializes in creating advanced cell therapies that work by controlling and augmenting the immune system. RegCell's approach involves returning regulatory T cells and activating them in vitro, allowing for effective treatment options for patients facing these challenging health conditions. By targeting unmet medical needs, RegCell aims to improve patient outcomes and provide new hope for those suffering from autoimmune disorders and cancer.

Neusignal Therapeutics is a medical company focused on developing small molecule drugs aimed at treating dementia and psychiatric disorders. The company is engaged in research and development initiatives designed to address various central nervous system diseases, striving to provide therapeutic solutions for patients suffering from brain health issues. By targeting these challenging conditions, Neusignal Therapeutics aims to improve the quality of life for individuals affected by cognitive and psychiatric challenges.

Medii, Ltd. is a Tokyo-based company founded in 2020 that designs and develops a medical system platform focused on addressing the shortage of specialists in community medicine. The company operates an e-consulting platform that offers online specialist consultation services, facilitating medical treatment for patients through e-consulting and e-opinion options. By providing on-site consulting to medical institutions, Medii enables clinics and healthcare providers to access specialist knowledge and experience, ultimately assisting patients in regions where specialist care is limited. The company's innovative approach aims to eliminate clinical questions and concerns, enhancing the overall quality of healthcare delivery.

A10 Lab Inc. is a Tokyo-based company that specializes in developing a self-improvement mobile application aimed at helping users form teams of five to support one another through chat-based interactions. Founded in 2016, the company focuses on promoting happiness and well-being through technology, independent of any major corporate affiliations. Its flagship application, 'Min Chale,' leverages gamification and social encouragement to facilitate the development of new routines among users. By fostering collaboration and accountability within small groups, A10 Lab aims to enhance individuals' skills and improve their overall quality of life, while also driving profits for partner companies by increasing user engagement and lifetime value.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

CellFiber Co., Ltd., established in 2015 and headquartered in Tokyo, Japan, specializes in the development and sale of cell-laden soft materials. The company focuses on creating plug-and-play bio-manufacturing solutions using its proprietary CellFiber™ technology. This technology is designed to enhance yields and product quality, ensuring stability, predictability, reproducibility, and scalability for cell and gene therapy applications. By providing efficient cell mass production processes, CellFiber supports a wide range of applications from research to clinical use, ultimately lowering costs and development timelines.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science to innovate in the treatment of diseases. The company focuses on harnessing the potential of the gut microbiome, applying its research to various fields including pharmaceuticals, healthcare, functional foods, and academic research. By promoting advancements in drug discovery, Metagen Therapeutics aims to contribute to a disease-free world. It operates as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science to innovate in the treatment of diseases. The company focuses on harnessing the potential of the gut microbiome, applying its research to various fields including pharmaceuticals, healthcare, functional foods, and academic research. By promoting advancements in drug discovery, Metagen Therapeutics aims to contribute to a disease-free world. It operates as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science to innovate in the treatment of diseases. The company focuses on harnessing the potential of the gut microbiome, applying its research to various fields including pharmaceuticals, healthcare, functional foods, and academic research. By promoting advancements in drug discovery, Metagen Therapeutics aims to contribute to a disease-free world. It operates as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd.

Varinos Inc. is a clinical testing company based in Tokyo, Japan, founded in 2017. It specializes in genomic testing and continuous clinical sequencing services, partnering with medical institutions to provide advanced contract analysis. Utilizing next-generation sequencing technology, Varinos offers services such as endometrial microbiome testing and flow of intrauterine flora testing. The company's innovative genome analysis capabilities enable the detection of microscopic amounts of bacteria and facilitate the examination of genes and chromosomes in embryos before pregnancy, thereby assisting women in identifying potential abnormalities and reducing associated physical and mental burdens.

reverSASP Therapeutics is focused on developing innovative drugs aimed at treating aging-related diseases by targeting senescent cells. The company leverages its deep understanding of the biology underlying these conditions, particularly the Senescence-associated secretory phenotype (SASP), to create therapeutic solutions. By addressing the challenges posed by declining birthrates and an aging population, reverSASP Therapeutics aims to extend healthy life expectancy and improve the quality of life for older individuals. Its research emphasizes the unique properties of inflammatory senescent cells, which are linked to various age-related diseases, positioning the company as a key player in the field of longevity and healthspan enhancement.

mediPhone, Inc. is a company based in Minato, Japan, specializing in medical interpretation services. Founded in 2014, it aims to eliminate language barriers in healthcare by providing telephone and video medical interpreter services. The company offers a range of solutions, including a medical translation application, assistance with hospitalization guidance, and the dispatch of interpreters for advanced treatments and medical checkups. Through these services, mediPhone facilitates access to healthcare for clients in various regions, ensuring they receive necessary medical care without the challenges posed by language differences.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

A10 Lab Inc. is a Tokyo-based company that specializes in developing a self-improvement mobile application aimed at helping users form teams of five to support one another through chat-based interactions. Founded in 2016, the company focuses on promoting happiness and well-being through technology, independent of any major corporate affiliations. Its flagship application, 'Min Chale,' leverages gamification and social encouragement to facilitate the development of new routines among users. By fostering collaboration and accountability within small groups, A10 Lab aims to enhance individuals' skills and improve their overall quality of life, while also driving profits for partner companies by increasing user engagement and lifetime value.

Fast Doctor Co., Ltd., established in 2016 and headquartered in Tokyo, Japan, specializes in providing in-home emergency medical care services during off-hours, including nights and holidays. The company arranges these services through partnerships with medical institutes and offers them via a mobile application. Their services cover a wide range of medical issues, from minor ailments like fever and headache to more serious conditions such as fractures and animal bites. They provide triage, medical examinations, prescriptions, and settlement services, aiming to reduce the burden on ambulance and emergency care systems by offering prompt, convenient care.

Braizon Therapeutics, Inc. is a biopharmaceutical company based in Tokyo, Japan, founded in 2015. It focuses on the research and development of innovative drug delivery technologies specifically aimed at treating central nervous system disorders. The company was established through collaborative research efforts led by prominent academics from the University of Tokyo and Tokyo Medical and Dental University. Braizon’s primary objective is to create effective methods for delivering therapeutic drugs across the blood-brain barrier, thereby addressing the challenges associated with treating incurable neuronal diseases. Through its advanced platform, Braizon Therapeutics seeks to enhance the efficacy of treatments for patients suffering from various central nervous system conditions.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science to innovate in the treatment of diseases. The company focuses on harnessing the potential of the gut microbiome, applying its research to various fields including pharmaceuticals, healthcare, functional foods, and academic research. By promoting advancements in drug discovery, Metagen Therapeutics aims to contribute to a disease-free world. It operates as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd.

RIN Institute Inc., established in 2016 and headquartered in Tokyo, Japan, specializes in research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company focuses on creating antibody-based treatments and diagnostics for various types of cancer, aiming to improve patient outcomes and recovery chances.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

Fast Doctor Co., Ltd., established in 2016 and headquartered in Tokyo, Japan, specializes in providing in-home emergency medical care services during off-hours, including nights and holidays. The company arranges these services through partnerships with medical institutes and offers them via a mobile application. Their services cover a wide range of medical issues, from minor ailments like fever and headache to more serious conditions such as fractures and animal bites. They provide triage, medical examinations, prescriptions, and settlement services, aiming to reduce the burden on ambulance and emergency care systems by offering prompt, convenient care.

Cytlimic Inc. is a biotechnology company based in Japan, founded on December 16, 2016. The company focuses on the development of cancer peptide vaccines and conducts clinical trials and nonclinical testing for these innovative therapies. Cytlimic's primary aim is to create immunotherapy products that activate the immune system to target and attack cancer cells, allowing patients to maintain a high quality of life during treatment. By leveraging advanced knowledge in cancer immunology, Cytlimic strives to provide effective solutions for overcoming cancer through its investigational vaccines.

PuREC is a biotechnology company focused on developing advanced culture technologies to enhance treatment efficacy. The company specializes in rapidly evolving cell therapies and mesenchymal stem cell therapies. Its innovative approach addresses specific medical conditions, including hypophosphatasia, a rare bone-formation deficiency affecting newborns, and spinal canal stenosis, which is often caused by disc herniation. By leveraging its technological advancements, PuREC aims to empower healthcare providers in their efforts to combat various diseases and transform the landscape of transplantation medicine.

RIN Institute Inc., established in 2016 and headquartered in Tokyo, Japan, specializes in research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company focuses on creating antibody-based treatments and diagnostics for various types of cancer, aiming to improve patient outcomes and recovery chances.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

VELDT Inc. is a Tokyo-based company founded in 2012 that specializes in developing wearable technology and Internet of Things (IoT) products. The company is known for its innovative smartwatches, including the VELDT SERENDIPITY, which combines traditional analog design with modern connectivity features. These devices are designed to help users regain time spent on smartphones, encouraging them to explore their surroundings and discover new experiences. VELDT's products, which also include luxury timepieces, aim to enhance daily routines by providing valuable data related to fitness and health through a blend of transparent light and discreet displays. The company serves a global customer base through retail outlets in Japan and online platforms, gaining recognition for its functional design and clear conceptual approach to technology.

mediPhone, Inc. is a company based in Minato, Japan, specializing in medical interpretation services. Founded in 2014, it aims to eliminate language barriers in healthcare by providing telephone and video medical interpreter services. The company offers a range of solutions, including a medical translation application, assistance with hospitalization guidance, and the dispatch of interpreters for advanced treatments and medical checkups. Through these services, mediPhone facilitates access to healthcare for clients in various regions, ensuring they receive necessary medical care without the challenges posed by language differences.

PENTAS Inc. is a Tokyo-based company founded in 2015 that specializes in the development of medical analysis software and devices. The company's focus includes creating innovative solutions for cerebral aneurysm fluid analysis and the design of intracranial stents. As a subsidiary of Allm Inc., PENTAS is dedicated to advancing medical technology to improve patient outcomes and enhance clinical practices in the field of neurology.

Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.

Yukashikado Inc. is a Tokyo-based company founded in 2013 that specializes in developing personal nutrition testing products. The company offers postal nutrition testing kits that allow individuals to evaluate their nutritional status by analyzing urine samples for various nutrients, including proteins, vitamins, and minerals. By providing results that can be accessed through personal computers and smartphones, Yukashikado enables users to monitor their nutritional levels and make informed decisions about their dietary intake. The company's focus on personal nutrition aims to support overall health and wellness, making it easier for consumers to understand and manage their nutritional needs from the comfort of their homes.

Braizon Therapeutics, Inc. is a biopharmaceutical company based in Tokyo, Japan, founded in 2015. It focuses on the research and development of innovative drug delivery technologies specifically aimed at treating central nervous system disorders. The company was established through collaborative research efforts led by prominent academics from the University of Tokyo and Tokyo Medical and Dental University. Braizon’s primary objective is to create effective methods for delivering therapeutic drugs across the blood-brain barrier, thereby addressing the challenges associated with treating incurable neuronal diseases. Through its advanced platform, Braizon Therapeutics seeks to enhance the efficacy of treatments for patients suffering from various central nervous system conditions.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.

CellBank Corp. is a Tokyo-based company founded in 2004 that specializes in cell storage, regenerative medical technology, and the cosmetics sector. The company operates within the framework of regulations governing the safety of regenerative medicine, focusing on innovative solutions in the field. CellBank is dedicated to advancing technologies that support both medical and cosmetic applications, positioning itself as a key player in the intersection of these industries.

RIN Institute Inc., established in 2016 and headquartered in Tokyo, Japan, specializes in research and development of medicines and external diagnostic drugs based on monoclonal antibodies. The company focuses on creating antibody-based treatments and diagnostics for various types of cancer, aiming to improve patient outcomes and recovery chances.

NB Health Laboratory Co. Ltd. is a biotechnology company located in Kawaguchi, Japan, focused on the research and development of innovative drugs targeting respiratory diseases, chronic inflammation, and infectious diseases. The company operates a research platform for screening small compounds in vitro and producing functional monoclonal antibodies. It engages in contract research, co-development, and licensing activities, offering DAP Kinase inhibitors aimed at treating stroke and heart diseases. Additionally, NB Health Laboratory conducts research programs for conditions such as chronic obstructive pulmonary disease (COPD), aneurysms, and skin wrinkles, as well as drug and functional monoclonal antibody screening programs. Its products are utilized in addressing various vascular diseases, including atherosclerosis, stroke, and vascular disorders associated with diabetes mellitus, alongside treatments for acute and chronic inflammatory diseases and sleep disorders.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

VELDT Inc. is a Tokyo-based company founded in 2012 that specializes in developing wearable technology and Internet of Things (IoT) products. The company is known for its innovative smartwatches, including the VELDT SERENDIPITY, which combines traditional analog design with modern connectivity features. These devices are designed to help users regain time spent on smartphones, encouraging them to explore their surroundings and discover new experiences. VELDT's products, which also include luxury timepieces, aim to enhance daily routines by providing valuable data related to fitness and health through a blend of transparent light and discreet displays. The company serves a global customer base through retail outlets in Japan and online platforms, gaining recognition for its functional design and clear conceptual approach to technology.

VELDT Inc. is a Tokyo-based company founded in 2012 that specializes in developing wearable technology and Internet of Things (IoT) products. The company is known for its innovative smartwatches, including the VELDT SERENDIPITY, which combines traditional analog design with modern connectivity features. These devices are designed to help users regain time spent on smartphones, encouraging them to explore their surroundings and discover new experiences. VELDT's products, which also include luxury timepieces, aim to enhance daily routines by providing valuable data related to fitness and health through a blend of transparent light and discreet displays. The company serves a global customer base through retail outlets in Japan and online platforms, gaining recognition for its functional design and clear conceptual approach to technology.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.

NIL is a bio-tech company that develops innovative and functional ultrafine particle technology based on many years of research experience.

Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.

NIL provides services including planning, development, maintenance, and sales of various software development tools, research and development linked to software engineering, and more. It also offers services like system and software development, maintenance, sales, and consultation. It offers software tools for use with things like automotive and medical systems.

ReasonWhy Inc., founded on July 7, 2011, is a Japan-based company that specializes in healthcare IT services. The company offers a suite of innovative solutions designed to enhance communication and information access within the medical field. Its key services include Whytlink, a social network tailored for medical professionals; Findme, an online platform that connects patients with doctors for second opinions; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy aims to improve healthcare delivery and facilitate better patient outcomes.

Cytlimic Inc. is a biotechnology company based in Japan, founded on December 16, 2016. The company focuses on the development of cancer peptide vaccines and conducts clinical trials and nonclinical testing for these innovative therapies. Cytlimic's primary aim is to create immunotherapy products that activate the immune system to target and attack cancer cells, allowing patients to maintain a high quality of life during treatment. By leveraging advanced knowledge in cancer immunology, Cytlimic strives to provide effective solutions for overcoming cancer through its investigational vaccines.

NB Health Laboratory Co. Ltd. is a biotechnology company located in Kawaguchi, Japan, focused on the research and development of innovative drugs targeting respiratory diseases, chronic inflammation, and infectious diseases. The company operates a research platform for screening small compounds in vitro and producing functional monoclonal antibodies. It engages in contract research, co-development, and licensing activities, offering DAP Kinase inhibitors aimed at treating stroke and heart diseases. Additionally, NB Health Laboratory conducts research programs for conditions such as chronic obstructive pulmonary disease (COPD), aneurysms, and skin wrinkles, as well as drug and functional monoclonal antibody screening programs. Its products are utilized in addressing various vascular diseases, including atherosclerosis, stroke, and vascular disorders associated with diabetes mellitus, alongside treatments for acute and chronic inflammatory diseases and sleep disorders.

ReasonWhy Inc., founded on July 7, 2011, is a Japan-based company that specializes in healthcare IT services. The company offers a suite of innovative solutions designed to enhance communication and information access within the medical field. Its key services include Whytlink, a social network tailored for medical professionals; Findme, an online platform that connects patients with doctors for second opinions; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy aims to improve healthcare delivery and facilitate better patient outcomes.

Braizon Therapeutics, Inc. is a biopharmaceutical company based in Tokyo, Japan, founded in 2015. It focuses on the research and development of innovative drug delivery technologies specifically aimed at treating central nervous system disorders. The company was established through collaborative research efforts led by prominent academics from the University of Tokyo and Tokyo Medical and Dental University. Braizon’s primary objective is to create effective methods for delivering therapeutic drugs across the blood-brain barrier, thereby addressing the challenges associated with treating incurable neuronal diseases. Through its advanced platform, Braizon Therapeutics seeks to enhance the efficacy of treatments for patients suffering from various central nervous system conditions.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

PuREC is a biotechnology company focused on developing advanced culture technologies to enhance treatment efficacy. The company specializes in rapidly evolving cell therapies and mesenchymal stem cell therapies. Its innovative approach addresses specific medical conditions, including hypophosphatasia, a rare bone-formation deficiency affecting newborns, and spinal canal stenosis, which is often caused by disc herniation. By leveraging its technological advancements, PuREC aims to empower healthcare providers in their efforts to combat various diseases and transform the landscape of transplantation medicine.

CellSeed Inc. is a biotechnology company based in Tokyo, Japan, specializing in the development of regenerative medicine products primarily for the Japanese and European markets. Founded in 2001, the company focuses on research, development, manufacture, and marketing of cell-sheet regenerative medicine products. These include epithelial cell sheets for corneal and esophageal regeneration, as well as regenerated cartilage sheets for treating knee osteoarthritis and cardiac patches for heart disease. In addition to its regenerative medicine offerings, CellSeed provides innovative cell cultureware solutions, such as UpCell and RepCell, designed for cell-sheet engineering and collection, respectively. The company also engages in contract development and manufacturing services, further expanding its capabilities in the biotechnology sector.

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, specializing in the development of innovative cancer immunotherapy drugs. The company is advancing its lead candidate, ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for the treatment of prostate cancer. Additionally, BrightPath is developing GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. The company also has research-stage products, including GRN-1301, a neoantigen targeting drug-resistant tumors in non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Founded in 2003, BrightPath Biotherapeutics aims to stimulate potent immune responses to tumor-associated antigens through its peptide vaccine technology.

ProbeX is a company specializing in the development and manufacturing of molecular imaging technology. It focuses on creating and distributing molecular imaging probe reagents that are essential for drug discovery. In addition to its core products, ProbeX also offers consulting services related to research tools in the field of molecular imaging. Through its innovative solutions, the company aims to advance the capabilities of researchers in various scientific domains.

Japan Medical Information Research Institute focuses on the collection, analysis, and marketing of medical information. The organization provides consulting services to help clients understand and utilize medical data effectively. Through its expertise in medical information, the institute aims to enhance the decision-making processes within the healthcare sector.

CellSeed Inc. is a biotechnology company based in Tokyo, Japan, specializing in the development of regenerative medicine products primarily for the Japanese and European markets. Founded in 2001, the company focuses on research, development, manufacture, and marketing of cell-sheet regenerative medicine products. These include epithelial cell sheets for corneal and esophageal regeneration, as well as regenerated cartilage sheets for treating knee osteoarthritis and cardiac patches for heart disease. In addition to its regenerative medicine offerings, CellSeed provides innovative cell cultureware solutions, such as UpCell and RepCell, designed for cell-sheet engineering and collection, respectively. The company also engages in contract development and manufacturing services, further expanding its capabilities in the biotechnology sector.

Chiome Bioscience Inc. is a Japanese biotechnology company founded in 2005, specializing in the research and development of innovative drug discovery technologies. The company is renowned for its ADLib System, a proprietary monoclonal antibody generation technology designed to facilitate drug discovery and development. Chiome offers a variety of services, including protein expression and purification, stable cell line generation, and antibody generation using advanced techniques. Its product pipeline features several therapeutic candidates targeting various cancers and diseases, such as ADCT-701 for liver cancer and CBA-1205 for multiple cancer types. Chiome collaborates with universities, research institutions, and pharmaceutical companies to advance its projects, including a partnership with Velabs Therapeutics focused on antibody discovery. With a strategic shift towards drug development following a merger in 2015, Chiome is committed to enhancing its clinical capabilities and increasing corporate value through innovative therapeutic solutions. The company is headquartered in Tokyo, Japan.